Cargando…
Tolvaptan therapy of Chinese cirrhotic patients with ascites after insufficient diuretic routine medication responses: a phase III clinical trial
BACKGROUND: To determine the safety and efficacy of different doses of tolvaptan for treating Chinese cirrhotic patients with or without hyponatraemia who still had ascites after routine therapy with diuretics. METHODS: In the present placebo-controlled, randomized, double-blinded, multicentre clini...
Autores principales: | Tang, Jieting, Wang, Yongfeng, Han, Tao, Mao, Qing, Cheng, Jun, Ding, Huiguo, Shang, Jia, Zhang, Qin, Niu, Junqi, Ji, Feng, Chen, Chengwei, Jia, Jidong, Jiang, Xiangjun, Lv, Nonghua, Gao, Yueqiu, Wang, Zhenghua, Wei, Zhong, Chen, Yingxuan, Zeng, Minde, Mao, Yimin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7678173/ https://www.ncbi.nlm.nih.gov/pubmed/33213378 http://dx.doi.org/10.1186/s12876-020-01536-0 |
Ejemplares similares
-
Impact of continued administration of tolvaptan on cirrhotic patients with ascites
por: Kogiso, Tomomi, et al.
Publicado: (2018) -
Management of Cirrhotic Ascites under the Add-on Administration of Tolvaptan
por: Adachi, Takuya, et al.
Publicado: (2021) -
Tolvaptan treatment improves survival of cirrhotic patients with ascites and hyponatremia
por: Wang, Shuzhen, et al.
Publicado: (2018) -
Early Administration of Tolvaptan Can Improve Survival in Patients with Cirrhotic Ascites
por: Hosui, Atsushi, et al.
Publicado: (2021) -
Cisterna chyli as an optimal marker of tolvaptan response in severe cirrhotic ascites
por: Hirooka, Masashi, et al.
Publicado: (2022)